Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ~7% of human malignancies and ~60% of melanomas(1). Early clinical experience with a novel class I RAF-selective inhibitor, PLX4032, demonstrated an unprecedented 80% anti-tumour response rate among patients with B-RAF(V600E)-pos...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nazarian, Ramin, Shi, Hubing, Wang, Qi, Kong, Xiangju, Koya, Richard C., Lee, Hane, Chen, Zugen, Lee, Mi-Kyung, Attar, Narsis, Sazegar, Hooman, Chodon, Thinle, Nelson, Stanley F., McArthur, Grant, Sosman, Jeffrey A., Ribas, Antoni, Lo, Roger S.
Format:	Artigo
Language:	Inglês
Published:	2010
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3143360/ https://ncbi.nlm.nih.gov/pubmed/21107323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature09626
Tags:	Add Tag No Tags, Be the first to tag this record!

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Similar Items